The trademark application ADENOVERSE was filed by Precigen, Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on September 3, 2023, and it was registered by office on December 11, 2023 without any oppositions.
The application was filed in English (Italian was selected as the second language).
Goods And Services
The mark was filed in class 42 with following description of goods:
Scientific and technological services and biological research and development relating thereto, namely, research and development utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of immune cells
Scientific and technological services and biological research and development, namely, research and development related to treatment of complex diseases
Medical research in the field of immunotherapy.
The mark was filed in class 44 with Medical services, namely, providing medical therapy treatments for patients in the fields of oncology, rare diseases, metabolic disorders, infectious diseases, ophthalmology, and cardiovascular diseases.